Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 17/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 17/20 | 1.00 |
| ▸ | NPC1 | O15118 | 11/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.83 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.81 |
| ▸ | ATM | Q13315 | 2/20 | 0.72 |
| ▸ | CASP3 | P42574 | 1/20 | 0.66 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.66 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.65 |
| ▸ | FNTA | P49354 | 1/20 | 0.63 |
| ▸ | FNTB | P49356 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16971009 | 1.00 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AECE2 | |
| SCHEMBL16970997 | 0.86 | MEN1 (0.84) | MEN1KMT2ANPC1RAB9AECE2 | |
| SCHEMBL16970999 | 0.86 | MEN1 (0.84) | MEN1KMT2ANPC1RAB9AECE2 | |
| SCHEMBL16970987 | 0.82 | MEN1 (0.70) | MEN1KMT2ANPC1RAB9AECE2 | |
| SCHEMBL16970988 | 0.82 | MEN1 (0.70) | MEN1KMT2ANPC1RAB9AECE2 | |
| SCHEMBL12316856 | 0.81 | MEN1 (0.75) | MEN1KMT2ANPC1RAB9AECE2 | |
| SCHEMBL14507045 | 0.80 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9AECE2 | |
| SCHEMBL12282409 | 0.79 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AECE2 | |
| SCHEMBL14426512 | 0.79 | KMT2A (0.69) | MEN1KMT2ANPC1RAB9AECE2 | |
| SCHEMBL12280972 | 0.79 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AECE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3147280-B1 | ANTI-ANGIOGENIC COMPOUND | UNIV COLLEGE DUBLIN NAT UNIV IRELAND DUBLIN (IE) | 2018-03-07 | — | — | EP | disclosed |
| US-9815788-B2 | Anti-angiogenic compounds | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2017-11-14 | — | — | US | disclosed |
| EP-3147280-A1 | ANTI-ANGIOGENIC COMPOUND | University College Dublin, National University of Ireland, Dublin (IE) | 2017-03-29 | — | — | EP | disclosed |
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-02-23 | — | — | US | disclosed |
| EP-2877454-B1 | ANTI-ANGIOGENIC 2-STYRYL-QUINOLINE COMPOUNDS | UNIV DUBLIN (IE) | 2016-11-02 | — | — | EP | disclosed |
| US-9388138-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-07-12 | — | — | US | disclosed |
| US-20150218100-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, VHL | MEN1 4178/4885KMT2A 3493/4885NPC1 2305/4885 |
| US-20150218100-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, VHL | MEN1 4178/4885KMT2A 3493/4885NPC1 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.